Study directors: Elysa Marco, MD and Kevin Shapiro, MD
Recruiting: Yes
Study Title: A randomized, double-blind, parallel group, placebo-controlled study to investigate the efficacy, safety, and tolerability of ML-004 in adolescents and adults with autism spectrum disorders (ASD)
Condition: Autism Spectrum Disorder
Purpose: The purpose of this study is to find out whether ML-004, an extended-release version of zolmitriptan, can support with sociability and emotional regulation in adults with ASD.
Inclusion criteria:
18-45 years old
Diagnosed (or suspected) Autism Spectrum Disorder
Seeking to strengthen social engagement skills
Uses fluent spoken language
Has a designated study partner who is also willing to participate
Exclusion criteria:
Seizures requiring current medication management
History of migraines
Unable to swallow tablets
Unstable medical or psychiatric illness
Currently using certain medications for ASD – contact our study team to discuss
Testing: ASD assessment, IQ assessment, psychiatric questionnaires, and medical evaluations
Frequency of visits: 10 visits (every 2-3 weeks) over 4 months
Costs: No costs will be charged for any of the study procedures.
Payment: In return for the time, effort, and travel expenses, adults with their study partners will be compensated $200 per visit
Location: Cortica Glendale
Coordinator: Kelly Olvany – kolvany@corticacare.com – (331) 272-1322
Fill out our Interest Form and we will contact you!